Russia develops bioartificial liver using patients’ own blood cells

Russia develops bioartificial liver using patients’ own blood cells
Russia develops bioartificial liver using patients’ own blood cells

Russian scientists are developing a bioartificial liver using cells derived from a patient’s own blood, a technology designed to support people with severe liver failure and potentially reduce the need for transplants in the future.

Clinical trials are expected to begin in Moscow in early 2027, according to Vladislav Garbuzov, head of the Russian capital’s Department of Investment and Industrial Policy.

The extracorporeal system is designed to filter blood, maintain metabolic functions and produce proteins. Initially, it would help patients remain stable while waiting for a liver transplant or allow their own liver to recover.

The project is being developed by Russian biotechnology company Artcellence in collaboration with specialists from the M. F. Vladimirski Moscow Regional Research Clinical Institute.

The technology uses induced pluripotent stem cells, which are created from blood cells and reprogrammed to function like liver cells. The method is based on research by Japanese scientist Shinya Yamanaka, who received the 2012 Nobel Prize in Medicine.

Unlike existing blood-cleansing systems such as MARS and Prometheus, the new approach is intended not only to filter blood but also to support protein synthesis and metabolism.

Because the system uses reprogrammed cells from the patient, developers say it could also avoid immune rejection.

The project’s long-term goal is to develop a more complete alternative to liver transplantation. However, the technology remains under development, and its effectiveness and safety will need to be evaluated through clinical trials.

Edith Báez

Journalist, broadcaster, social media manager, and content creator with a Master’s degree in Strategic Marketing

Related News